MarketFriction

Medico Remedies Ltd

NSE MEDICO · BSE 540937 · Pharmaceuticals
₹21.86 +1.53%
NSE close2026-10-01
52 week range20.47 - 56.88
Market cap₹181 Cr.
P/E13.1
ASM short-term Price band 10% Delivery 57.5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales42.3629.7741.3230.8039.3539.4941.3038.2552.6458.6856.8169.40
Expenses39.2927.0436.6727.9836.9436.3834.6435.4349.9154.3549.6666.10
Operating Profit3.072.734.652.822.413.116.662.822.734.337.153.30
OPM %7.25%9.17%11.25%9.16%6.12%7.88%16.13%7.37%5.19%7.38%12.59%4.76%
Other Income0.960.270.580.290.681.430.290.661.720.682.871.17
Interest0.180.220.250.180.210.280.490.280.240.390.900.41
Depreciation0.710.720.740.750.750.760.770.770.730.790.800.72
Profit before tax3.142.064.242.182.133.505.692.433.483.838.323.34
Tax %22.61%30.10%26.89%27.06%27.23%25.14%23.90%25.51%25.86%25.07%29.69%24.55%
Net Profit2.431.453.101.581.552.624.341.822.572.875.862.52
EPS in Rs0.290.170.370.190.190.320.520.220.310.350.710.30
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6754619889122121140145151206238
Expenses6350589586117114131132136189220
Operating Profit44333571013151718
OPM %5%7%6%2.8%3.2%4.3%6%7%9%10%8%7%
Other Income001221242366
Interest112111111122
Depreciation111222233333
Profit before tax22222461011141819
Tax %40%4%35%28%26%30%26%28%27%25%27%
Net Profit121223578101314
EPS in Rs0.350.250.150.190.200.310.580.871.001.221.581.67
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth12%11%14%50%
Compounded Profit Growth28%38%22%34%
Stock Price CAGR%11%-32%-54%
Return on Equity14%17%18%19%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital22344441717171717
Reserves121313232426282027364659
Borrowings8141913141415131081419
Other Liabilities141713203532282834364359
Total Liabilities36464859767576778796120153
Fixed Assets87771213151822212120
CWIP003412000003
Investments110000101222
Other Assets2738394863605959647396129
Total Assets36464859767576778796120153
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-3551-1168256
Cash from Investing Activity-3-5-4-3-17-2-7-3-3-5
Cash from Financing Activity6-1-1318-6-2-0-1-1
Net Cash Flow-0-0-00-10-2-0-111
Free Cash Flow-431-2-2832-021
CFO/OP-68%162%198%53%-198%104%111%43%58%64%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days5310712210210998829294125138145
Inventory Days7663961257499587669549072
Days Payable122106112147149143100113108105117119
Cash Conversion Cycle6641058033543954547511198
Working Capital Days2153110884961505254749084
ROCE %10%11%10%9%8%8%10%15%21%21%21%23%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters73.34%73.34%73.34%73.34%73.34%66.83%63.79%62.59%61.38%61.38%61.38%61.38%
FIIs1.11%1.29%0.29%0.22%0.22%0.39%0.11%0.07%0.30%0.49%0.03%0.08%
DIIs0.00%0.00%0.74%0.97%0.97%0.78%0.01%0.01%0.01%0.00%0.00%0.00%
Public25.55%25.36%25.63%25.46%25.47%32.00%36.08%37.33%38.30%38.13%38.60%38.55%
No. of Shareholders5,2646,05210,68512,90212,88714,10415,42416,47418,50316,56216,18915,863

Fundamentals

Market Cap₹ 181 Cr.
Current Price₹ 21.8
Stock P/E13.1
Book Value₹ 9.10
ROCE23.3 %
ROE19.0 %
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)50%
Compounded Profit Growth (TTM)34%
Standalone figures.
Valuation
Market capRs 181 Cr
Enterprise valueRs 198 Cr
P/E (TTM)13.13x
Price to book2.40x
Price to sales0.76x
EV / EBITDA8.28x
EV / EBIT9.49x
EV / sales0.84x
Price to cash flow30.90x
Earnings yield7.62%
P/E, 3-year average37.09x
P/B, 3-year average6.02x
P/E, 5-year average40.62x
P/B, 5-year average6.61x
Profitability
Operating margin (excl. other income)8.25%
Operating margin (incl. other income)11.13%
EBITDA margin10.08%
Pre-tax margin7.99%
Net profit margin5.82%
Net margin, latest quarter3.63%
ROE19.02%
ROCE23.28%
ROA9.60%
ROE, 3-year average17.94%
ROCE, 3-year average22.01%
ROA, 3-year average9.33%
ROE, 5-year average17.15%
ROCE, 5-year average20.38%
ROA, 5-year average8.61%
ROIC (approx.)16.41%
Tax rate27.41%
Other income / net worth7.86%
Growth
Sales growth (latest year)36.73%
Profit growth (latest year)30.03%
Sales CAGR, 3 years13.69%
Sales CAGR, 5 years11.02%
Profit CAGR, 3 years21.92%
Profit CAGR, 5 years38.33%
Sales growth QoQ22.16%
Profit growth QoQ-57.00%
Sales growth YoY (latest quarter)81.44%
Profit growth YoY (latest quarter)38.46%
Per share
EPS (TTM)Rs 1.67
EPS (latest year)Rs 1.58
EPS (latest quarter)Rs 0.30
EPS, 3-year averageRs 1.27
EPS, 5-year averageRs 1.51
Book value per shareRs 9.10
Sales per shareRs 28.62
Cash flow per shareRs 0.71
Free cash flow per shareRs 0.12
Efficiency
Asset turnover1.35x
Fixed asset turnover10.11x
Inventory turnover5.53x
Inventory days66 days
Debtor days145 days
Debtors turnover2.52x
Creditor days119 days
Cash conversion cycle98 days
Working capital days84 days
Leverage
Total debtRs 19 Cr
Cash and bankRs 2 Cr
Net debtRs 17 Cr
Debt to equity0.25x
Net debt / EBITDA0.71x
Interest coverage10.78x
Owners' fund to total sources49.20%
Debt to assets12.33%
Cash flow
Cash from Operating Activity (latest year)Rs 6 Cr
Cash from Investing Activity (latest year)Rs -5 Cr
Cash from Financing Activity (latest year)Rs -1 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs 1 Cr
FCFE (approx.: FCF + change in debt)Rs 6 Cr
Cash from ops / profit, 5 years0.63x
Sales to cash flow35.16x
Statement figures
Net sales (TTM)Rs 238 Cr
Net sales (latest year)Rs 206 Cr
Sales (latest quarter)Rs 69 Cr
Operating profit excl. other income (latest year)Rs 17 Cr
Operating profit (latest quarter)Rs 3 Cr
Other income (TTM)Rs 6 Cr
EBITDA (TTM)Rs 24 Cr
PBDT (TTM)Rs 22 Cr
Profit before tax (TTM)Rs 19 Cr
Tax (latest year)Rs 5 Cr
Net profit (TTM)Rs 14 Cr
Net profit (latest year)Rs 13 Cr
Net profit (latest quarter)Rs 3 Cr
Depreciation (TTM)Rs 3 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 2 Cr
Cost of goods sold (latest year)Rs 166 Cr
Total expenditure (latest year)Rs 189 Cr
Total income (latest year)Rs 212 Cr
Share capitalRs 17 Cr
ReservesRs 59 Cr
Shareholders' fundsRs 75 Cr
Total assetsRs 153 Cr
Net blockRs 20 Cr
Capital work in progressRs 3 Cr
InvestmentsRs 2 Cr
ReceivablesRs 82 Cr
InventoryRs 30 Cr
Other liabilitiesRs 59 Cr
Shares outstanding (crore)8.30
Ownership
Promoter holding61.38% (-1.21 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 13.1 is at the 1th percentile of its own 8.6-year range (median 33.0, low 12.9, high 153.6).
P/B 2.40 is at the 35th percentile (median 4.66).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodMEDICONifty 50Difference
1 week-32.7%-2.8% -30.0 pts
1 month-43.8%-6.8% -37.0 pts
3 months-46.9%-7.6% -39.3 pts
6 months-33.3%+0.4% -33.7 pts
1 year-55.1%-9.9% -45.2 pts
2 years-54.0%-13.6% -40.4 pts
3 years-68.9%+14.2% -83.1 pts
5 years+62.0%+27.9% +34.2 pts

Red flags

F-score 5 of 8
explainWeak cash conversion Cash from operations was 42% of net profit over the last 3 years
lookRegulator order or action Regulator order or action 2026-06-03: Medico Remedies Limited has informed the Exchange about Action(s) taken or orders passed
lookOn NSE surveillance On NSE surveillance: ASM short-term
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹69 Cr +81.4% vs Jun 2025. Net profit ₹3 Cr +38.5%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2024-08-29Annual General Meeting
2023-08-17Annual General Meeting
2023-03-16Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share0.2000
2022-09-13Annual General Meeting
DateTypeWhat it says
2026-09-29Price movementSignificant movement in price has been observed in Medico Remedies Limited. The Exchange, in order to ensure that investors have latest relevant infor...
2026-09-29Price movementSignificant movement in price has been observed in Medico Remedies Limited. The Exchange, in order to ensure that investors have latest relevant infor...
2026-09-23Shareholder meetingVoting results.
2026-09-22Shareholder meetingProceedings of Annual General Meeting held on September 22, 2026
2026-08-29General UpdatesBook Closure Dates.
2026-08-29Shareholder meetingNotice of undefined to be held on September 22, 2026
2026-08-13Board meeting outcomeMedico Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-05Order winBagging/Receiving of orders/contracts
2026-08-03Price movementSignificant movement in price has been observed in Medico Remedies Limited. The Exchange, in order to ensure that investors have latest relevant infor...
2026-06-29Credit RatingCredit Rating
2026-06-03Regulatory actionAction(s) taken or orders passed
2026-06-01Disclosure under SEBI TakeovHarshit Mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acq...
2026-05-21Board meeting outcomeMedico Remedies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-04-16Regulatory actionAction(s) taken or orders passed
2026-02-24Regulatory actionAction(s) taken or orders passed
2026-02-18Change in Company Secretary/Appointment of Company Secretary/Compliance Officer
2026-02-12Board meeting outcomeMedico Remedies Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
2026-02-12Board meeting outcomeBoard meeting held on February 12, 2026.
2026-01-27Order winBagging/Receiving of orders/contracts
2026-01-20Order winBagging/Receiving of orders/contracts
2025-11-14Board meeting outcomeMedico Remedies Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
2025-11-14General UpdatesGeneral Updates
2025-11-07Awarding of order(s)/contracAwarding of order(s)/contract(s)
2025-10-06Awarding of order(s)/contracAwarding of order(s)/contract(s)
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Short Term Additional Surveillance Measure (Short Term ASM): stage 1
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03